Drug intelligence / Profile preview

VD1219

Development stage: Unknown
Lead developer: Weishen Pharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

VD1219 is an investigational small molecule drug being developed as a hepatitis B virus (HBV) capsid inhibitor. Its primary mechanism is believed to involve interference with the assembly or function of the HBV capsid, thereby inhibiting viral replication. The drug is administered orally and is currently in early-stage clinical development for chronic hepatitis B. The developer and sponsor of VD1219 is Weishen Pharmaceutical Technology (Shanghai) Co., Ltd.[1][5] As of now, detailed information about its precise molecular target or additional mechanisms has not been disclosed.

Targets

HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on VD1219.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VD1219.

Explore the full profile